Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma

Andrew L. Feldman, H. Richard Alexander, David L. Bartlett, Douglas L. Fraker, Steven K. Libutti

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Despite high rates of complete responses (CRs) to isolated limb perfusion (ILP) for patients with in-transit melanoma (60% to 90%), extremity recurrences are common. We evaluated our experience with managing these recurrences to determine how best to treat these patients. Methods: Between April 1992 and April 1998, 72 patients experienced CRs after hyperthermic ILP using Melphalan, with (n = 46) or without (n = 26) tumor necrosis factor. Of these, 25 patients (35%) experienced initial recurrences in the extremities, and they form the basis of this study. Results: Three patients who underwent repeat ILP for treatment of their recurrences experienced a second CR and recurrence in the extremity (at 9, 15, and 16 months), allowing analysis of 28 cases. For 5 of 20 recurrences managed with excision, 2 of 6 managed with repeat ILP, and 0 of 2 managed with systemic treatment, the patient was free of disease at the last follow-up examination (median follow-up period, 11 months). Conclusions: Isolated extremity recurrences after CRs to ILP occurred in 35% of patients. Initially, these could be managed successfully by excision or repeat ILP for the majority of patients (92%). We recommend excision of small-volume recurrent disease, reserving repeat ILP for patients with increasing numbers of lesions or increasing rapidity of in-field recurrences.

Original languageEnglish (US)
Pages (from-to)562-567
Number of pages6
JournalAnnals of Surgical Oncology
Volume6
Issue number6
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Melanoma
Extremities
Perfusion
Recurrence
Melphalan
Tumor Necrosis Factor-alpha
Therapeutics

Keywords

  • Complete response
  • Limb perfusion
  • Melanoma
  • Melphalan
  • Recurrence

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. / Feldman, Andrew L.; Alexander, H. Richard; Bartlett, David L.; Fraker, Douglas L.; Libutti, Steven K.

In: Annals of Surgical Oncology, Vol. 6, No. 6, 1999, p. 562-567.

Research output: Contribution to journalArticle

Feldman, Andrew L. ; Alexander, H. Richard ; Bartlett, David L. ; Fraker, Douglas L. ; Libutti, Steven K. / Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. In: Annals of Surgical Oncology. 1999 ; Vol. 6, No. 6. pp. 562-567.
@article{1394173bbb6d4b92b37358b43b0a2148,
title = "Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma",
abstract = "Background: Despite high rates of complete responses (CRs) to isolated limb perfusion (ILP) for patients with in-transit melanoma (60{\%} to 90{\%}), extremity recurrences are common. We evaluated our experience with managing these recurrences to determine how best to treat these patients. Methods: Between April 1992 and April 1998, 72 patients experienced CRs after hyperthermic ILP using Melphalan, with (n = 46) or without (n = 26) tumor necrosis factor. Of these, 25 patients (35{\%}) experienced initial recurrences in the extremities, and they form the basis of this study. Results: Three patients who underwent repeat ILP for treatment of their recurrences experienced a second CR and recurrence in the extremity (at 9, 15, and 16 months), allowing analysis of 28 cases. For 5 of 20 recurrences managed with excision, 2 of 6 managed with repeat ILP, and 0 of 2 managed with systemic treatment, the patient was free of disease at the last follow-up examination (median follow-up period, 11 months). Conclusions: Isolated extremity recurrences after CRs to ILP occurred in 35{\%} of patients. Initially, these could be managed successfully by excision or repeat ILP for the majority of patients (92{\%}). We recommend excision of small-volume recurrent disease, reserving repeat ILP for patients with increasing numbers of lesions or increasing rapidity of in-field recurrences.",
keywords = "Complete response, Limb perfusion, Melanoma, Melphalan, Recurrence",
author = "Feldman, {Andrew L.} and Alexander, {H. Richard} and Bartlett, {David L.} and Fraker, {Douglas L.} and Libutti, {Steven K.}",
year = "1999",
doi = "10.1007/s10434-999-0562-x",
language = "English (US)",
volume = "6",
pages = "562--567",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma

AU - Feldman, Andrew L.

AU - Alexander, H. Richard

AU - Bartlett, David L.

AU - Fraker, Douglas L.

AU - Libutti, Steven K.

PY - 1999

Y1 - 1999

N2 - Background: Despite high rates of complete responses (CRs) to isolated limb perfusion (ILP) for patients with in-transit melanoma (60% to 90%), extremity recurrences are common. We evaluated our experience with managing these recurrences to determine how best to treat these patients. Methods: Between April 1992 and April 1998, 72 patients experienced CRs after hyperthermic ILP using Melphalan, with (n = 46) or without (n = 26) tumor necrosis factor. Of these, 25 patients (35%) experienced initial recurrences in the extremities, and they form the basis of this study. Results: Three patients who underwent repeat ILP for treatment of their recurrences experienced a second CR and recurrence in the extremity (at 9, 15, and 16 months), allowing analysis of 28 cases. For 5 of 20 recurrences managed with excision, 2 of 6 managed with repeat ILP, and 0 of 2 managed with systemic treatment, the patient was free of disease at the last follow-up examination (median follow-up period, 11 months). Conclusions: Isolated extremity recurrences after CRs to ILP occurred in 35% of patients. Initially, these could be managed successfully by excision or repeat ILP for the majority of patients (92%). We recommend excision of small-volume recurrent disease, reserving repeat ILP for patients with increasing numbers of lesions or increasing rapidity of in-field recurrences.

AB - Background: Despite high rates of complete responses (CRs) to isolated limb perfusion (ILP) for patients with in-transit melanoma (60% to 90%), extremity recurrences are common. We evaluated our experience with managing these recurrences to determine how best to treat these patients. Methods: Between April 1992 and April 1998, 72 patients experienced CRs after hyperthermic ILP using Melphalan, with (n = 46) or without (n = 26) tumor necrosis factor. Of these, 25 patients (35%) experienced initial recurrences in the extremities, and they form the basis of this study. Results: Three patients who underwent repeat ILP for treatment of their recurrences experienced a second CR and recurrence in the extremity (at 9, 15, and 16 months), allowing analysis of 28 cases. For 5 of 20 recurrences managed with excision, 2 of 6 managed with repeat ILP, and 0 of 2 managed with systemic treatment, the patient was free of disease at the last follow-up examination (median follow-up period, 11 months). Conclusions: Isolated extremity recurrences after CRs to ILP occurred in 35% of patients. Initially, these could be managed successfully by excision or repeat ILP for the majority of patients (92%). We recommend excision of small-volume recurrent disease, reserving repeat ILP for patients with increasing numbers of lesions or increasing rapidity of in-field recurrences.

KW - Complete response

KW - Limb perfusion

KW - Melanoma

KW - Melphalan

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=0032840437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032840437&partnerID=8YFLogxK

U2 - 10.1007/s10434-999-0562-x

DO - 10.1007/s10434-999-0562-x

M3 - Article

VL - 6

SP - 562

EP - 567

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -